Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
N Engl J Med. Author manuscript; available in PMC 2012 March 8.
Published in final edited form as:
PMCID: PMC3205971

Genetic Basis for In Vivo Daptomycin Resistance in Enterococci

Cesar A. Arias, M.D., Ph.D., Diana Panesso, Ph.D., Danielle M. McGrath, Ph.D., Xiang Qin, Ph.D., Maria F. Mojica, M.Sc., Corwin Miller, B.A., Lorena Diaz, B.Sc., Truc T. Tran, Pharm.D., Sandra Rincon, M.Sc., E. Magda Barbu, Ph.D., Jinnethe Reyes, M.Sc., Jung H. Roh, Ph.D., Elizabeth Lobos, Ph.D., Erica Sodergren, Ph.D., Renata Pasqualini, Ph.D., Wadih Arap, M.D., Ph.D., John P. Quinn, M.D., Yousif Shamoo, Ph.D., Barbara E. Murray, M.D., and George M. Weinstock, Ph.D.



Daptomycin is a lipopeptide with bactericidal activity that acts on the cell membrane of enterococci and is often used off-label to treat patients infected with vancomycin-resistant enterococci. However, the emergence of resistance to daptomycin during therapy threatens its usefulness.


We performed whole-genome sequencing and characterization of the cell envelope of a clinical pair of vancomycin-resistant Enterococcus faecalis isolates from the blood of a patient with fatal bacteremia; one isolate (S613) was from blood drawn before treatment and the other isolate (R712) was from blood drawn after treatment with daptomycin. The minimal inhibitory concentrations (MICs) of these two isolates were 1 and 12 μg per milliliter, respectively. Gene replacements were made to exchange the alleles found in isolate S613 with those in isolate R712.


Isolate R712 had in-frame deletions in three genes. Two genes encoded putative enzymes involved in phospholipid metabolism, GdpD (which denotes glycerophosphoryl diester phosphodiesterase) and Cls (which denotes cardiolipin synthetase), and one gene encoded a putative membrane protein, LiaF (which denotes lipid II cycle-interfering antibiotics protein but whose exact function is not known). LiaF is predicted to be a member of a three-component regulatory system (LiaFSR) involved in the stress-sensing response of the cell envelope to antibiotics. Replacement of the liaF allele of isolate S613 with the liaF allele from isolate R712 quadrupled the MIC of daptomycin, whereas replacement of the gdpD allele had no effect on MIC. Replacement of both the liaF and gdpD alleles of isolate S613 with the liaF and gdpD alleles of isolate R712 raised the daptomycin MIC for isolate S613 to 12 μg per milliliter. As compared with isolate S613, isolate R712 — the daptomycin-resistant isolate — had changes in the structure of the cell envelope and alterations in membrane permeability and membrane potential.


Mutations in genes encoding LiaF and a GdpD-family protein were necessary and sufficient for the development of resistance to daptomycin during the treatment of vancomycin-resistant enterococci. (Funded by the National Institute of Allergy and Infectious Diseases and the National Institutes of Health.)

The treatment of enterococcal infections has become an enormous challenge for clinicians because these organisms frequently exhibit resistance to the standard drugs of choice — namely, ampicillin, vancomycin, and aminoglycosides (with high-level resistance to aminoglycosides). In addition, there has been a striking increase in the frequency of isolation and the spread of vancomycin-resistant enterococci in hospitals around the world, which has resulted in significant increases in mortality, length of hospital stay, and hospitalization costs.1

Enterococcus faecium is one of the so-called ESKAPE pathogens (E. faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and enterobacter species) flagged by the Infectious Diseases Society of America as problem pathogens requiring new therapies.2 The Food and Drug Administration (FDA) has approved only two compounds for the treatment of vancomycin-resistant enterococci infections: linezolid and quinupristin–dalfopristin. Both have important limitations when used for the treatment of severe vancomycin-resistant infection. Their use often results in clinical failure or recurrence of infection; they have an adverse toxicity profile, a limited spectrum of activity, and a bacteriostatic effect against vancomycin-resistant enterococci, and they are associated with increasing reports of resistance.

Daptomycin is a lipopeptide antibiotic with in vitro bactericidal activity against enterococci. Even though the FDA has not approved daptomycin for the treatment of infection with vancomycin-resistant enterococci, clinicians often use it off-label in patients with severe enterococcal infections because of the lack of other treatment options with established reliability.3 However, a major drawback of the use of daptomycin for the treatment of infection with vancomycin-resistant enterococci is the development of resistance during therapy.46 Although little is known about the mechanism of in vivo resistance, a critical step in the action of daptomycin is its interaction with the bacterial cell membrane in a calcium-dependent manner. In this study, comparative genomic sequencing and genetic manipulations of a clinical pair of daptomycin-susceptible and daptomycin-resistant E. faecalis strains, which were recovered from the bloodstream of a patient with fatal bacteremia, identified mutations in two genes not previously associated with antibiotic resistance in enterococci.



The vancomycin-resistant clinical strain pair of daptomycin-susceptible and daptomycin-resistant E. faecalis has been described previously,4 as has a similar strain pair of E. faecium5 (for details, see the Supplementary Appendix, available with the full text of this article at We also studied, with the use of pulsed-field gel electrophoresis, six unrelated clinical isolates of daptomycin-resistant enterococci (one E. faecalis isolate and five E. faecium isolates) recovered from different clinical sources in the United States. A daptomycin-resistant derivative of E. faecalis S613 was obtained after passing the bacterium through increasing subinhibitory concentrations of daptomycin twice daily for 17 days, starting with a concentration of 0.5 μg per milliliter. (See the Supplementary Appendix for the selection protocol.)


Paired-end sequence reads of the E. faecalis strain pair (S613 and R712) were generated with the Illumina Genome Analyzer IIx at the Washington University Genome Institute, producing 100 base-paired end reads that were assembled with the use of Velvet software.7 Genomic analysis and comparisons were performed by applying standard methods (see the Supplementary Appendix for details). All synonymous and nonsynonymous mutations were confirmed by means of polymerase-chain-reaction (PCR) sequencing of both strands in accordance with the Sanger dideoxyterminator method of sequencing, with target genes re-sequenced in their entirety. The homologues of the genes encoding the LiaFSR regulatory system (liaF, liaS, and liaR [lia denotes lipid II cycle-interfering antibiotics protein]),8 the glycerophosphoryl-diester-phosphodiesterase (gdpD)–family protein, and cardiolipin synthetase (cls) were sequenced from all isolates and derivatives of S613.


To establish a direct link between the presence of specific gene mutations and the development of the daptomycin-resistant phenotype, we replaced the native genes encoding the LiaF and GdpD proteins of the E. faecalis S613 isolate with those of the E. faecalis R712 isolate. The replacements were performed independently for each gene and then in combination, with the use of the p-chlorophenylalanine sensitivity counterselection system, as described previously,9,10 except for the fact that plasmid pHOU3 was constructed and used (Fig. S1 in the Supplementary Appendix). The mutants were characterized with the use of pulsed-field gel electrophoresis, and the open reading frames of the three genes (liaF, cls, and gdpD) were sequenced. To detect small differences in the susceptibility to daptomycin, minimal inhibitory concentrations (MICs) were determined with the use of Etest (AB Biodisk).11


Transmission electron microscopy was used to assess the ultrastructural characteristics of E. faecalis strain pair S613 and R712 in accordance with standard methods.12 The number of cell-division events (cells with a septum) in 100 cells chosen randomly in two blinded experiments was also determined with the use of transmission electron microscopy. The thickness of the cell walls was measured from the outer border of the cell membrane to the outer edge of the cell wall (on the basis of 100 observations of each isolate with a minimum of 50 cells, in cells from different fields, at a magnification of 190,000). The mean (±SD) cell-wall thickness was determined for each strain, and mean differences were compared with the use of Student’s t-test.

Cell-surface charge, daptomycin-mediated cell-membrane permeability, and the effect of daptomycin on cell-membrane potential were measured with the use of a modified cytochrome c assay,13 a highly sensitive bacterial viability kit (LIVE/DEAD BacLight, Invitrogen),14 and the cell-membrane potential-sensitive 3,3-dipentyoxacarbocyanine assay,15 respectively (see the Supplementary Appendix for details).



A total of 3082 open reading frames were found in isolate S613 (2,727,367 base pairs were matched in both genomes), and comparative analysis and resequencing of genes of the clinical strain pair revealed changes in four predicted proteins in the daptomycin-resistant isolate, R712, as compared with the daptomycin-susceptible isolate, S613. Three of the four mutations consisted of in-frame deletions in a stretch encoding a repeated amino acid (Table 1). The proteins encoded included two enzymes (GdpD and Cls) predicted to be involved in phospholipid metabolism and likely to participate in cell-membrane homeostasis and a putative transmembrane protein that is a homologue of LiaF (48% similarity) from Bacillus subtilis8 (Table 1). The regions of these predicted proteins are highly conserved among all E. faecalis isolates whose genomes have been sequenced, and these deletions are unique to the daptomycin-resistant isolate as compared with all E. faecalis homologues analyzed ( The fourth mutated gene encodes a putative LacI (lactose-operon-repressor)-family transcriptional repressor that is probably involved in carbohydrate metabolism. However, the substitution (Gly Val) in position 2 is also present in other enterococcal homologues of the putative protein. It is of interest that none of the enterococcal homologues of staphylococcal genes associated with daptomycin resistance in previous studies (mprF, yycG, yycH, dltABCD, rpoB, rpoC, vraSR, and graSR)2024 exhibited any change when their gene sequences were compared with those of the vancomycin-resistant E. faecalis clinical strain pair.

Table 1
Genetic Changes Identified in the Vancomycin-Resistant Enterococcus faecalis Isolate That Was Resistant to Daptomycin (Strain R712) as Compared with the Daptomycin-Susceptible Isolate (Strain S613).*

To confirm the association of the genetic changes (Table 1) with the development of daptomycin-resistance, we initially exposed the daptomycin-susceptible E. faecalis S613 isolate to increasing concentrations of daptomycin in vitro. A daptomycin-resistant derivative was readily obtained after 17 days of exposure, with a daptomycin MIC similar to that of R712 (isolate S613R) (Table 2). On pulsed-field gel electrophoresis, the S613R isolate had a pattern that was identical to that of isolate S613, and we identified the same mutations found in the genes encoding the LiaF protein and the GdpD enzyme (but not in cls), suggesting that gdpD and liaF play a predominant role in the development of resistance to daptomycin in this in vitro–selected mutant.

Table 2
Amino Acid Changes in Daptomycin-Susceptible and Daptomycin-Resistant Clinical and Laboratory-Derived Isolates of Vancomycin-Resistant Enterococcus faecalis.*

To establish a direct link between the mutations in these two genes and the development of resistance to daptomycin, we replaced the liaF and gdpD alleles of the S613 isolate with those derived from the R712 isolate, both individually and in combination (with liaF replaced first, followed by gdpD). The correct allelic replacements were confirmed by sequencing the corresponding entire open reading frames in all constructs (including the cls gene that was not manipulated and remained unchanged in all constructs). Table 2 shows that the introduction of the liaF allele of the R712 isolate quadrupled the daptomycin MIC of the S613 isolate but not to the level of the R712 isolate; replacement of the gdpD allele alone had no effect on the susceptibility of isolate S613 to daptomycin. However, when the gdpD allelic replacement was introduced into the S613 derivative harboring the deletion in liaF, the daptomycin MIC was increased to 12 μg per milliliter — a concentration that was above the clinical breakpoint and identical to that for isolate R712, confirming our in vitro observation that mutations in these two genes are necessary and sufficient to confer clinical resistance to daptomycin in E. faecalis isolate S613.


Transmission electron microscopy revealed important differences in the cell morphology of the two isolates; R712 cells tended to clump and formed aggregates with longer chains, as compared with S613 cells. At higher magnifications, the presence of multiple septal structures before complete cell separation was evident in R712 (Fig. 1). In addition, the R712 cell envelopes appeared to be markedly altered as compared with those of the S613 isolate (Fig. 1). The number of cells with a septum was consistently higher in the R712 isolate than in the S613 isolate (P<0.001). The cell-wall thickness of R712 was also greater than that of S613 (average thickness, 18.12±2.23 nm vs. 10.43±1.34 nm; P<0.001). Collectively, our results suggest that the development of daptomycin resistance in vivo in E. faecalis is associated with profound ultrastructural changes in the cell envelope, septal apparatus, and cell wall. The development of daptomycin resistance in R712 was also associated with a cell surface with a greater positive charge, striking reductions in daptomycin-induced permeabilization of the cell membrane, and alterations in the ability of daptomycin to depolarize the membrane of the target cell, as compared with isolate S613 (Fig. S2 in the Supplementary Appendix).

Figure 1
Transmission Electron Microscopy of the Cell Envelope of Enterococcus faecalis Isolates, One Susceptible to Daptomycin (S613) and the Other Resistant (R712)


We sought to determine whether the genetic changes identified in the daptomycin-resistant strain of E. faecalis (Table 1) could also be found in other clinical isolates of daptomycin-resistant enterococci, particularly E. faecium, since infection with this species is much more difficult to treat than infection with E. faecalis. Indeed, in a clinical strain pair of E. faecium recovered from a patient before and after daptomycin therapy, we found an Arg218 Gln substitution in the Cls enzyme but not in the LiaFSR or GdpD proteins (Table 3). The Arg218 Gln substitution in Cls was also found in an unrelated daptomycin-resistant clinical isolate of E. faecium (isolate R501) (Table 3), suggesting that this switch in amino acids (within the phospholipase D domain of the enzyme) may play an important role in the development of daptomycin resistance in E. faecium. Furthermore, we invariably found changes in cls, liaF, liaS, or liaR in other daptomycin-resistant clinical isolates of enterococci (Table 3).

Table 3
Changes in Genes Encoding Cls or Members of the LiaFSR System in Clinical Isolates of Enterococci.*


The off-label use of daptomycin occurs often in the treatment of severe enterococcal infections, including infections with vancomycin-resistant enterococci or those species exhibiting high-level resistance to aminoglycosides. However, a major drawback for the successful use of this antibiotic is the emergence of resistance during therapy. In addition, in vitro, enterococci are less susceptible to daptomycin than S. aureus, with a clinical threshold for sensitivity that is four times as high (≤4 μg per milliliter, vs. ≤1 μg per milliliter for S. aureus).25

An essential event for the activity of daptomycin is calcium-mediated interaction with the cell membrane, a property that this antibiotic shares with related cationic antimicrobial peptides that are part of the human host defense against microbes. The change in the bacterial surface also appears to play an important role in the interaction of daptomycin with the cell membrane, and it has been postulated that a more positively charged cell envelope “repels” the cationic daptomycin from the cell membrane, contributing to the development of resistance.15 A major factor in the cell-envelope charge is the phospholipid composition of the inner and outer cell-membrane leaflets, such as the negatively charged phospholipid cardiolipin and the positively charged amino derivatives of phosphatidylglycerol. In some S. aureus isolates, reduced susceptibility to daptomycin has been attributed to a decrease in the negative surface charge of the cell membrane as a result of modifications in phospholipid content, mainly through increased synthesis and translocation (“flipping”) of the positively charged lysyl-phosphatidylglycerol from the inner to the outer leaflet of the cell membrane.15,26 It has also been shown that lysyl-phosphatidylglycerol attenuates membrane perturbations caused by cationic antimicrobial peptides.27

Our findings in this study indicate that the development of resistance to daptomycin in the vancomycin-resistant E. faecalis isolate R712, like the development of resistance in S. aureus, is associated with alterations in the cell envelope and biophysical properties of the cell membrane. However, the genes linked to these changes in enterococci appear to be different from those described in S. aureus. Indeed, in the R712 isolate, none of the genes associated with the emergence of resistance to daptomycin in S. aureus2024 differed from those in the daptomycin-susceptible parental isolate, S613. Instead, our data provide direct evidence that changes in two genes — namely, liaF and gdpD — are sufficient for the development of resistance to daptomycin in the E. faecalis clinical strain pair.

The alteration of the LiaFSR system is probably a pivotal initial event in the development of resistance, since replacement of only the liaF allele in the S613 isolate with that from the R712 isolate decreased the susceptibility of the S613 isolate to daptomycin.

LiaF is part of the three-component LiaFSR regulatory system, which is known to orchestrate the response of the cell envelope to antibiotics and antimicrobial peptides in some gram-positive bacteria. The LiaFSR system has been well characterized in B. subtilis,8,16 Streptococcus mutans,17 and pneumococci.18 In B. subtilis and S. mutans, the LiaFSR system is usually activated by the presence of antibiotics that disrupt cell-membrane and peptidoglycan synthesis through alterations of lipid-II metabolism (i.e., bacitracin, daptomycin, ramoplanin, nisin, and vancomycin).16,19 In B. subtilis, LiaF is a membrane-anchored, negative regulator of LiaS (which is the sensor protein of the system and also functions as a histidine kinase that phosphorylates the cognate-response regulator, LiaR).8 Therefore, it is predicted that mutations in liaF may release the inhibitory effect of LiaS, resulting in activation of this system.

Nonetheless, our genetic experiments indicated that mutations in liaF are not sufficient for full expression of the resistant phenotype. Indeed, the subsequent introduction of a mutation in gdpD was sufficient to increase the MIC to a level similar to that in the daptomycin-resistant R712 isolate, indicating that both genes are needed for the full expression of the resistant phenotype. Thus, it appears that resistance to daptomycin in enterococci requires two major steps. First, an initial activation of the LiaFSR system occurs through mutations in liaF or other components of the LiaFSR system (which might be selected by means of exposure to antibiotics that alter lipid-II metabolism); activation of the system may influence cell-envelope homeostasis by affecting the transcription of several genes that can help mitigate the damage caused by the antibiotic. Second, a subsequent alteration in the cell membrane occurs through changes in enzymes involved in phospholipid metabolism (e.g., GdpD or Cls), leading to critical and compensatory changes in the composition or distribution of phospholipids in the cell membrane. Indeed, the bacterial GdpD has been shown to be important in glycerol metabolism, hydrolyzing several cell-membrane glycerophosphodiesters28 that affect phospholipid metabolism. Similarly, cardiolipin has been found to play several key roles in cell-membrane physiology, such as in bacterial cell division,29,30 transporter localization (in Escherichia coli),31 and the triggering of compensatory changes in the phospholipid composition of the cell membrane, which affect bacterial adaptive responses.32

In support of our hypothesis that the changes discussed above are also important in other daptomycin-resistant isolates of enterococci, we found changes in genes encoding the LiaFSR system and Cls in three additional clinical isolates of daptomycin-resistant enterococci. In four other daptomycin-resistant clinical isolates, only one of these genes appeared to be altered, suggesting that additional loci involved in cell-wall homeostasis or phospholipid metabolism may be important in these enterococcal isolates. Indeed, unlike the S. aureus cell membrane, the enterococcal cell membrane has several amino acid–containing phospholipids, apart from lysyl-phosphatidylglycerol (including arginyl-phosphatidylglycerol and alanyl-phosphatidylglycerol33). In addition, there are other two-component systems present in enterococci that can potentially modulate the response to the antimicrobial challenge.

It is also of interest that the amino acid changes in the LiaF and GdpD proteins of the R712 isolate occurred in a region that harbors repeats of Ile; this suggests that these in-frame changes may have originated from recombination between adjacent repetitive nucleotide sequences. Mutations that occur by means of this mechanism were observed to alter the function of LiaF in B. subtilis8 and the histidine kinase VanSB involved in E. faecium resistance to vancomycin,34 and these mutations suggest the presence of an underlying genetic mechanism for the development of resistance to daptomycin in E. faecalis.

In summary, our data indicate that the emergence of resistance to daptomycin is the result of concomitant alterations in genes (liaF and gdpD) encoding proteins that are probably involved in regulating the stress response to antimicrobial agents acting on the cell envelope and enzymes that are responsible for phospholipid metabolism in the cell membrane.

Supplementary Material



Supported by grants from the National Institute of Allergy and Infectious Diseases (Pathway to Independence Award R00 AI72961, to Dr. Arias; R01 AI067861 and R37 AI47923, to Dr. Murray; and R01 AI080714, to Dr. Shamoo) and a grant for genome sequencing from the National Institutes of Health (1U54 HG004968, to Dr. Weinstock).

We thank Silvia Munoz-Price, James H. Jorgensen, Helio Sader, Ronald Jones, Chris Pillar, and Daniel Sahm for providing the enterococcal isolates; Arnold S. Bayer, Jared Silverman, and Pablo Okhuysen for useful discussions; and Kevin Morano, I-Hsiu Huang, and Hung Ton-That for technical assistance with the cell-membrane and electron-microscopy experiments.


Disclosure forms provided by the authors are available with the full text of this article at


1. DiazGranados CA, Zimmer SM, Klein M, Jernigan JA. Comparison of mortality associated with vancomycin-resistant and vancomycin-susceptible enterococcal bloodstream infections: a meta-analysis. Clin Infect Dis. 2005;41:327–33. [PubMed]
2. Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE!: an update from the Infectious Diseases Society of America. Clin Infect Dis. 2009;48:1–12. [PubMed]
3. Cantón R, Ruiz-Garbajosa P, Chaves RL, Johnson AP. A potential role for daptomycin in enterococcal infections: what is the evidence? J Antimicrob Chemother. 2010;65:1126–36. [PMC free article] [PubMed]
4. Munoz-Price LS, Lolans K, Quinn JP. Emergence of resistance to daptomycin during treatment of vancomycin-resistant Enterococcus faecalis infection. Clin Infect Dis. 2005;41:565–6. [PubMed]
5. Lewis JS, II, Owens A, Cadena J, Sabol K, Patterson JE, Jorgensen JH. Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy. Antimicrob Agents Chemother. 2005;49:1664–5. [Erratum, Antimicrob Agents Chemother 2005;49:2152.] [PMC free article] [PubMed]
6. Green MR, Anasetti C, Sandin RL, Rolfe NE, Greene JN. Development of daptomycin resistance in a bone marrow transplant patient with vancomycin-resistant Enterococcus durans. J Oncol Pharm Pract. 2006;12:179–81. [PubMed]
7. Zerbino DR, Birney E. Velvet: algorithms for de novo short read assembly using de Bruijn graphs. Genome Res. 2008;18:821–9. [PubMed]
8. Jordan S, Junker A, Helmann JD, Mascher T. Regulation of LiaRS-dependent gene expression in Bacillus subtilis: identification of inhibitor proteins, regulator binding sites, and target genes of a conserved cell envelope stress-sensing two-component system. J Bacteriol. 2006;188:5153–66. [PMC free article] [PubMed]
9. Kristich CJ, Chandler JR, Dunny GM. Development of a host-genotype-independent counterselectable marker and a high-frequency conjugative delivery system and their use in genetic analysis of Enterococcus faecalis. Plasmid. 2007;57:131–44. [PMC free article] [PubMed]
10. Panesso D, Montealegre MC, Rincón S, et al. The hylEfm gene in pHylEfm of Enterococcus faecium is not required in pathogenesis of murine peritonitis. BMC Microbiol. 2011;11:20. [PMC free article] [PubMed]
11. Etest technical manual. Dalvägen Solna, Sweden: AB Biodisk; 2008. Simplify your MIC testing with Etest daptomycin + calcium.
12. Hayat MA. Principles and techniques of electron microscopy: biological applications. 4. Cambridge, United Kingdom: Cambridge University Press; 2000.
13. Mukhopadhyay K, Whitmire W, Xiong YQ, et al. In vitro susceptibility of Staphylococcus aureus to thrombin-induced platelet microbicidal protein-1 (tPMP-1) is influenced by cell membrane phospholipid composition and asymmetry. Microbiology. 2007;153:1187–97. [PubMed]
14. Leuko S, Legat A, Fendrihan S, Stan-Lotter H. Evaluation of the LIVE/DEAD BacLight kit for detection of extremophilic archaea and visualization of microorganisms in environmental hypersaline samples. Appl Environ Microbiol. 2004;70:6884–6. [PMC free article] [PubMed]
15. Jones T, Yeaman MR, Sakoulas G, et al. Failures in clinical treatment of Staphylococcus aureus infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding. Antimicrob Agents Chemother. 2008;52:269–78. [PMC free article] [PubMed]
16. Wolf D, Kalamorz F, Wecke T, et al. In-depth profiling of the LiaR response of Bacillus subtilis. J Bacteriol. 2010;192:4680–93. [PMC free article] [PubMed]
17. Suntharalingam P, Senadheera MD, Mair RW, Levesque CM, Cvitkovitch DG. The LiaFSR system regulates the cell envelope stress response in Streptococcus mutans. J Bacteriol. 2009;191:2973–84. [PMC free article] [PubMed]
18. Eldholm V, Gutt B, Johnsborg O, et al. The pneumococcal cell envelope stress-sensing system LiaFSR is activated by murein hydrolases and lipid II-interacting antibiotics. J Bacteriol. 2010;192:1761–73. [PMC free article] [PubMed]
19. Mascher T, Zimmer SL, Smith TA, Helmann JD. Antibiotic-inducible promoter regulated by the cell envelope stress-sensing two-component system LiaRS of Bacillus subtilis. Antimicrob Agents Chemother. 2004;48:2888–96. [PMC free article] [PubMed]
20. Ernst CM, Staubitz P, Mishra NN, et al. The bacterial defensin resistance protein MprF consists of separable domains for lipid lysinylation and antimicrobial peptide repulsion. PLoS Pathog. 2009;5(11):e1000660. [PMC free article] [PubMed]
21. Yang SJ, Kreiswirth BN, Sakoulas G, et al. Enhanced expression of dltABCD is associated with the development of daptomycin nonsusceptibility in a clinical endocarditis isolate of Staphylococcus aureus. J Infect Dis. 2009;200:1916–20. [PMC free article] [PubMed]
22. Mwangi MM, Wu SW, Zhou Y, et al. Tracking the in vivo evolution of multi-drug resistance in Staphylococcus aureus by whole-genome sequencing. Proc Natl Acad Sci U S A. 2007;104:9451–6. [PubMed]
23. Cui L, Neoh HM, Shoji M, Hiramatsu K. Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother. 2009;53:1231–4. [PMC free article] [PubMed]
24. Friedman L, Alder JD, Silverman JA. Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus. Antimicrob Agents Chemother. 2006;50:2137–45. [PMC free article] [PubMed]
25. Performance standards for antimicrobial susceptibility testing: twentieth informational supplement. Wayne, PA: Clinical and Laboratory Standards Institute; 2010. (CLSI document M100-S20.)
26. Yang SJ, Xiong YQ, Dunman PM, et al. Regulation of mprF in daptomycinnonsusceptible Staphylococcus aureus strains. Antimicrob Agents Chemother. 2009;53:2636–7. [PMC free article] [PubMed]
27. Kilelee E, Pokorny A, Yeaman MR, Bayer AS. Lysyl-phosphatidylglycerol attenuates membrane perturbation rather than surface association of the cationic antimicrobial peptide 6W-RP-1 in a model membrane system: implications for daptomycin resistance. Antimicrob Agents Chemother. 2010;54:4476–9. [PMC free article] [PubMed]
28. Schwan TG, Battisti JM, Porcella SF, et al. Glycerol-3-phosphate acquisition in spirochetes: distribution and biological activity of glycerophosphodiester phosphodiesterase (GlpQ) among Borrelia species. J Bacteriol. 2003;185:1346–56. [PMC free article] [PubMed]
29. Mileykovskaya E, Dowhan W. Cardiolipin membrane domains in prokaryotes and eukaryotes. Biochim Biophys Acta. 2009;1788:2084–91. [PMC free article] [PubMed]
30. Koppelman CM, Den Blaauwen T, Duursma MC, Heeren RM, Nanninga N. Escherichia coli minicell membranes are enriched in cardiolipin. J Bacteriol. 2001;183:6144–7. [PMC free article] [PubMed]
31. Romantsov T, Helbig S, Culham DE, Gill C, Stalker L, Wood JM. Cardiolipin promotes polar localization of osmosensory transporter ProP in Escherichia coli. Mol Microbiol. 2007;64:1455–65. [PubMed]
32. Shibuya I, Miyazaki C, Ohta A. Alteration of phospholipid composition by combined defects in phosphatidylserine and cardiolipin synthases and physiological consequences in Escherichia coli. J Bacteriol. 1985;161:1086–92. [PMC free article] [PubMed]
33. dos Santos Mota JM, den Kamp JA, Verheij HM, van Deenen LL. Phospholipids of Streptococcus faecalis. J Bacteriol. 1970;104:611–9. [PMC free article] [PubMed]
34. Depardieu F, Courvalin P, Msadek T. A six amino acid deletion, partially overlapping the VanSB G2 ATP-binding motif, leads to constitutive glycopeptide resistance in VanB-type Enterococcus faecium. Mol Microbiol. 2003;50:1069–83. [PubMed]